Bouvel Investment Partners LLC Reduces Stake in Cerus Co. (NASDAQ:CERS)

Bouvel Investment Partners LLC trimmed its position in shares of Cerus Co. (NASDAQ:CERS) by 1.6% during the fourth quarter, Holdings Channel reports. The firm owned 496,782 shares of the biotechnology company’s stock after selling 8,238 shares during the quarter. Bouvel Investment Partners LLC’s holdings in Cerus were worth $765,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Cerus by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock worth $7,685,000 after buying an additional 69,950 shares during the last quarter. Barclays PLC raised its position in Cerus by 16.2% during the third quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock worth $2,740,000 after acquiring an additional 219,755 shares during the last quarter. State Street Corp grew its position in shares of Cerus by 2.2% in the third quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock valued at $6,506,000 after purchasing an additional 79,505 shares during the last quarter. Stifel Financial Corp grew its position in shares of Cerus by 12.0% in the third quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock valued at $461,000 after purchasing an additional 28,383 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Cerus by 13.8% during the 3rd quarter. Franklin Resources Inc. now owns 93,763 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 11,338 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Stock Performance

Shares of NASDAQ CERS opened at $1.82 on Friday. The company has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $1.89. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The company has a market cap of $337.99 million, a PE ratio of -16.55 and a beta of 1.27. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.59.

Insider Buying and Selling

In other news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now owns 162,133 shares in the company, valued at $288,596.74. This trade represents a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus lowered their target price on Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.